New antibiotic combo tested in kidney patients

NCT ID NCT07104162

Recruiting now Knowledge-focused Sponsor: Qpex Biopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing a single dose of an experimental antibiotic combination (cefiderocol/xeruborbactam) given through a vein. The goal is to see how safe it is and how the body processes it in 40 adults with different levels of kidney function, including those on dialysis. The results will help determine the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cefiderocol/Xeruborbactam (a combination of two antibiotics given through a vein)
What this could lead to: If successful, this study will help doctors understand how to safely dose this antibiotic combination in patients with kidney problems, potentially leading to better treatment for serious bacterial infections.
What could go wrong: This is a very early (Phase 1) study with only 40 people, focused on safety and drug levels, not on curing infections. It may not lead to a new treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BACTERIAL INFECTIONS

Contacts and locations

Locations

Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
University of Miami Clinical Pharmacology
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.